General Health

Global Cardiovascular Therapeutics Market 2020-2024 | Increasing Use of Advanced Diagnostics to Boost Growth | Technavio

Friday, July 10, 2020 - 10:30pm

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40101

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40101
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our cardiovascular therapeutics market report covers the following areas:
    This study identifies the advent of novel oral anticoagulants (NOACs) as one of the prime reasons driving the cardiovascular therapeutics market growth during the next few years.
  • Backed with competitive intelligence and benchmarking, our research reports on the cardiovascular therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Closing of $135.7 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option To Purchase Additional Shares

Friday, July 10, 2020 - 9:15pm

The Company, sponsored by RA Capital Management, L.P., is led by Chairman and CEO Peter Kolchinsky PhD and CFO Matthew Hammond PhD.

Key Points: 
  • The Company, sponsored by RA Capital Management, L.P., is led by Chairman and CEO Peter Kolchinsky PhD and CFO Matthew Hammond PhD.
  • The Company is a blank check company formed for the purpose of effecting a business combination with one or more businesses in the healthcare industry.
  • The Companys shares of Class A common stock began trading on The Nasdaq Capital Market under the ticker symbol TXAC on July 8, 2020.
  • This press release contains statements that constitute forward-looking statements, including with respect to the initial public offering and the anticipated use of the net proceeds.

Global mHealth Market Review 2018-2019 and Forecast 2020-2026 - Featuring Profiles of Apple, AT&T, Orange, Google, Qualcomm, Telefonica, Vodafone Group, and Samsung Electronics Amongst Others - ResearchAndMarkets.com

Friday, July 10, 2020 - 5:01pm

The "mHealth Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "mHealth Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report predicts the global mHealth market to grow with a CAGR of 23.05% over the forecast period from 2020-2026.
  • The report on the global mHealth market provides qualitative and quantitative analysis for the period from 2018 to 2026.
  • The report on mHealth market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global mHealth market over the period of 2018 to 2026.

Outlook on the Obstructive Sleep Apnea Global Market (2020 to 2024) - Develop Tactics and Strategies to Take Advantage of Opportunities - ResearchAndMarkets.com

Friday, July 10, 2020 - 5:01pm

This report provides comprehensive insights into the Obstructive Sleep Apnea pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Obstructive Sleep Apnea pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Obstructive Sleep Apnea market size and drug sales.
  • This research covers the following: Obstructive Sleep Apnea treatment options, Obstructive Sleep Apnea late stage clinical trials pipeline, Obstructive Sleep Apnea prevalence by countries, Obstructive Sleep Apnea market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Obstructive Sleep Apnea pipeline: Find out drugs in clinical trials for the treatment of Obstructive Sleep Apnea by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Obstructive Sleep Apnea drugs: Identify key drugs marketed and prescribed for Obstructive Sleep Apnea in the US, including trade name, molecule name, and company
    Obstructive Sleep Apnea drugs sales: Find out the sales value for Obstructive Sleep Apnea drugs by countries
    Obstructive Sleep Apnea market valuations: Find out the market size for Obstructive Sleep Apnea drugs in 2019 by countries.

Worldwide Cystic Fibrosis Industry to 2024 - Develop In-Depth Knowledge of Competition and Markets - ResearchAndMarkets.com

Friday, July 10, 2020 - 4:48pm

This report provides comprehensive insights into the Cystic Fibrosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.

Key Points: 
  • This report provides comprehensive insights into the Cystic Fibrosis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Cystic Fibrosis market size and drug sales.
  • This research covers the following: Cystic Fibrosis treatment options, Cystic Fibrosis late stage clinical trials pipeline, Cystic Fibrosis prevalence by countries, Cystic Fibrosis market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Cystic Fibrosis pipeline: Find out drugs in clinical trials for the treatment of Cystic Fibrosis by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Cystic Fibrosis drugs: Identify key drugs marketed and prescribed for Cystic Fibrosis in the US, including trade name, molecule name, and company
    Cystic Fibrosis market valuations: Find out the market size for Cystic Fibrosis drugs in 2019 by countries.

World Population Day 2020: DKT International Addresses Global Supply Chain Disruption, Shipping and Distribution Delays, Limited Access to Healthcare Providers to Help Women Avoid Unintended Pregnancies and Unsafe Abortions Amid COVID-19

Friday, July 10, 2020 - 3:26pm

As a result, DKT is focused on doing everything we can to minimize disruption in the access to and use of high-quality products.

Key Points: 
  • As a result, DKT is focused on doing everything we can to minimize disruption in the access to and use of high-quality products.
  • The reproductive health needs of women and men around the world are not on pause during this timeso we are continuing to address those needs.
  • DKT is also now providing face shields to shop owners so they can stay open without fear of infection.
  • Several DKT family planning efforts considering COVID-19 pivots include:
    Training providers virtually on protocols to ensure safety for providers and clients alike.

Company Profile for Reven, LLC

Friday, July 10, 2020 - 3:40pm

Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.

Key Points: 
  • Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.
  • Revens vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases.
  • Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world.
  • Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.

LTC Announces Date of Second Quarter 2020 Earnings Release, Conference Call and Webcast

Friday, July 10, 2020 - 2:30pm

LTC is a real estate investment trust (REIT) investing in seniors housing and health care properties primarily through sale-leasebacks, mortgage financing, joint-ventures and structured finance solutions including preferred equity and mezzanine lending.

Key Points: 
  • LTC is a real estate investment trust (REIT) investing in seniors housing and health care properties primarily through sale-leasebacks, mortgage financing, joint-ventures and structured finance solutions including preferred equity and mezzanine lending.
  • The portfolio is comprised of investments of approximately 50% seniors housing and 50% skilled nursing properties.
  • All statements other than historical facts contained in this press release are forward looking statements.
  • All forward looking statements included in this press release are based on information available to the Company on the date hereof, and LTC assumes no obligation to update such forward looking statements.

Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA

Friday, July 10, 2020 - 1:00pm

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia.
  • According to IQVIA, a leading healthcare data and analytics provider, U.S. annual sales for Fluphenazine Hydrochloride Tablets for the 12 months ended May 2020 were approximately $143 million.
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.
  • The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.

scPharmaceuticals Appoints Sara Bonstein to Board of Directors

Friday, July 10, 2020 - 1:00pm

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Sara Bonstein to its Board of Directors.

Key Points: 
  • scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Sara Bonstein to its Board of Directors.
  • Ms. Bonstein fills the vacancy created from Dorothy Colemans resignation from the Board of Directors.
  • We are also very pleased to welcome Sara to our Board of Directors.
  • I am honored to be appointed to serve as a member of the Board for scPharmaceuticals, said Ms. Bonstein.